Cargando…

Updated Review on Clinically-Relevant Properties of Delafloxacin

The extensive use of fluoroquinolones has been consequently accompanied by the emergence of bacterial resistance, which triggers the necessity to discover new compounds. Delafloxacin is a brand-new anionic non-zwitterionic fluoroquinolone with some structural particularities that give it attractive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turban, Adrien, Guérin, François, Dinh, Aurélien, Cattoir, Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451745/ https://www.ncbi.nlm.nih.gov/pubmed/37627661 http://dx.doi.org/10.3390/antibiotics12081241

Ejemplares similares

Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties
por: Jorgensen, Sarah C. J., et al.
Publicado: (2018)

Recent Trends in Antimicrobial Resistance among Anaerobic Clinical Isolates
por: Reissier, Sophie, et al.
Publicado: (2023)

Delafloxacin: design, development and potential place in therapy
por: Candel, Francisco Javier, et al.
Publicado: (2017)

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment
por: Hoover, Randall, et al.
Publicado: (2016)

Delafloxacin: First Global Approval
por: Markham, Anthony
Publicado: (2017)

Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline
por: Kocsis, Béla, et al.
Publicado: (2021)

Correction to: Delafloxacin: First Global Approval
por: Markham, Anthony
Publicado: (2018)

Profile of a Novel Anionic Fluoroquinolone—Delafloxacin
por: Tulkens, Paul M, et al.
Publicado: (2019)

The Role of Next-Generation Sequencing (NGS) in the Management of Tuberculosis: Practical Review for Implementation in Routine
por: Beviere, Marion, et al.
Publicado: (2023)

Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections
por: Scott, L. J.
Publicado: (2020)

Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
por: Hoover, Randall K., et al.
Publicado: (2017)

Safety of Delafloxacin: Focus on Adverse Events of Special Interest
por: Lodise, Thomas, et al.
Publicado: (2018)

Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
por: Corey, G Ralph, et al.
Publicado: (2019)

Efficacy of Delafloxacin against the Biothreat Pathogen Burkholderia pseudomallei
por: McCurdy, Sandra, et al.
Publicado: (2021)

Correction to: Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections
por: Scott, L. J.
Publicado: (2020)

P41 Use of delafloxacin in osteomyelitis: a case report
por: Vidwans, Madhuri, et al.
Publicado: (2023)

Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin
por: Kocsis, Bela, et al.
Publicado: (2016)

Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin
por: Righi, Elda, et al.
Publicado: (2018)

Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin
por: Sharma, Roopali, et al.
Publicado: (2020)

629. Emergence and Clonal Spread of Delafloxacin-Resistant S. aureus in Brooklyn, NY
por: Malik, Saquib, et al.
Publicado: (2019)

In Vitro Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Ureaplasma Species
por: Kong, Yingying, et al.
Publicado: (2022)

Evaluation of Delafloxacin against a Burkholderia pseudomallei Efflux Mutant Panel
por: McCurdy, Sandra P., et al.
Publicado: (2022)

Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial
por: McCurdy, Sandra, et al.
Publicado: (2020)

Overexpression of the Novel MATE Fluoroquinolone Efflux Pump FepA in Listeria monocytogenes Is Driven by Inactivation of Its Local Repressor FepR
por: Guérin, François, et al.
Publicado: (2014)

Human Target Attainment Probabilities for Delafloxacin against Escherichia coli and Pseudomonas aeruginosa
por: Hoover, Randall, et al.
Publicado: (2017)

Early detection of plasma d-lactate: Toward a new highly-specific biomarker of bacteraemia?
por: Lefèvre, Charles R., et al.
Publicado: (2023)

Development of Lipomer Nanoparticles for the Enhancement of Drug Release, Anti-Microbial Activity and Bioavailability of Delafloxacin
por: Anwer, Md. Khalid, et al.
Publicado: (2020)

Clinical Relevance of Gut Microbiota Alterations under the Influence of Selected Drugs—Updated Review
por: Mruk-Mazurkiewicz, Honorata, et al.
Publicado: (2023)

Current Update on Clinically Relevant Sleep Issues in Parkinson’s Disease: A Narrative Review
por: Suzuki, Keisuke
Publicado: (2021)

The in vitro activity of delafloxacin and comparator agents against bacterial pathogens isolated from patients with cancer
por: Gerges, Bahgat, et al.
Publicado: (2023)

In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014
por: Pfaller, M. A., et al.
Publicado: (2017)

Activity of Delafloxacin and Levofloxacin against Stenotrophomonas maltophilia at Simulated Plasma and Intrapulmonary pH Values
por: Vialichka, Alesia, et al.
Publicado: (2022)

An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies
por: Iffland, Kerstin, et al.
Publicado: (2017)

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
por: Haahr, Hanne, et al.
Publicado: (2014)

The Efficacy and Adverse Events of Delafloxacin for Treating Acute Bacterial Skin and Skin Structure Infections: A Systematic Review and Meta-Analysis
por: Tanvir, Syed Bilal, et al.
Publicado: (2020)

The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials
por: He, Rong, et al.
Publicado: (2022)

Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management
por: Preckel, Benedikt, et al.
Publicado: (2020)

Resistance development in Escherichia coli to delafloxacin at pHs 6.0 and 7.3 compared to ciprofloxacin
por: Bösch, Anja, et al.
Publicado: (2023)

Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
por: Bassetti, Matteo, et al.
Publicado: (2019)

Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
por: Giordano, Philip A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tmt0lcj23c6174s3hvrd29ejab